oxonic acid has been researched along with Hematologic Diseases in 9 studies
Oxonic Acid: Antagonist of urate oxidase.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
Excerpt | Relevance | Reference |
---|---|---|
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
" We aimed to assess the clinical efficacy and safety of S-1 combined with paclitaxel (PTX) for AGC by performing a systematic review and meta-analysis of the published studies." | 2.61 | S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis. ( Bian, NN; Min, GT; Wang, YH, 2019) |
" Severe adverse events were observed in 22 patients (91." | 1.42 | Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015) |
" Five patients showed grade 3 and 4 adverse reactions, all hematological." | 1.35 | Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. ( Ishikawa, K; Suzuki, S, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 8 (88.89) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bian, NN | 1 |
Wang, YH | 1 |
Min, GT | 1 |
Takahara, N | 1 |
Isayama, H | 1 |
Nakai, Y | 1 |
Sasaki, T | 1 |
Ishigami, H | 1 |
Yamashita, H | 1 |
Yamaguchi, H | 1 |
Hamada, T | 1 |
Uchino, R | 1 |
Mizuno, S | 1 |
Miyabayashi, K | 1 |
Mohri, D | 1 |
Kawakubo, K | 1 |
Kogure, H | 1 |
Yamamoto, N | 1 |
Sasahira, N | 1 |
Hirano, K | 1 |
Ijichi, H | 1 |
Tateishi, K | 1 |
Tada, M | 1 |
Kitayama, J | 1 |
Watanabe, T | 1 |
Koike, K | 1 |
Suzuki, S | 3 |
Honda, K | 1 |
Sato, T | 1 |
Yamazaki, K | 1 |
Ishikawa, K | 2 |
Soh, J | 1 |
Okumura, N | 1 |
Nakata, M | 1 |
Nakamura, H | 1 |
Fukuda, M | 1 |
Kataoka, M | 1 |
Kajiwara, S | 1 |
Sano, Y | 1 |
Aoe, M | 1 |
Kataoka, K | 1 |
Hotta, K | 1 |
Matsuo, K | 1 |
Toyooka, S | 1 |
Date, H | 1 |
Kobayashi, S | 1 |
Ueno, M | 1 |
Hara, H | 1 |
Irie, K | 1 |
Goda, Y | 1 |
Moriya, S | 1 |
Tezuka, S | 1 |
Tanaka, M | 1 |
Okusaka, T | 1 |
Ohkawa, S | 1 |
Morimoto, M | 1 |
Choi, IS | 1 |
Lee, KW | 1 |
Kim, KH | 1 |
Kim, YJ | 1 |
Kim, JH | 1 |
Lee, JS | 1 |
Sunaga, T | 1 |
Harada, N | 1 |
Hayashi, T | 1 |
Suzuki, M | 1 |
Shiroyama, T | 1 |
Komuta, K | 1 |
Imamura, F | 1 |
Hirashima, T | 1 |
Kijima, T | 1 |
Tachibana, I | 1 |
Kawase, I | 1 |
1 review available for oxonic acid and Hematologic Diseases
Article | Year |
---|---|
S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hematologic Diseases; Humans; Oxo | 2019 |
5 trials available for oxonic acid and Hematologic Diseases
Article | Year |
---|---|
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deox | 2016 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Surviv | 2011 |
3 other studies available for oxonic acid and Hematologic Diseases
Article | Year |
---|---|
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot | 2015 |
Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Sq | 2009 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |